Estradiol-Receptor Blockade in Older Men and Women

Normal Healthy Volunteers Clinical Trial

Official title:

Pilot Study of Estradiol-Receptor Blockade in Older Men and Women

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02271282
• Other study ID #: 14-004704
• Status: Completed
• Phase: Phase 1
• First received: October 17, 2014
• Last updated: September 12, 2016
• Start date: December 2014
• Est. completion date: May 2016

Study information

• Verified date: September 2016
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review BoardUnited States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Repletion of testosterone (Te) in older men drives GH secretion after its aromatization to estradiol (E2), which acts via the estrogen receptor (ER). Conversely, we postulate that estrogen deprivation in postmenopausal women attenuates growth hormone (GH) secretion and insulin-like growth factor-1 (IGF-I) production, thus favoring development of metabolic syndrome in men treated with toremifene, a new estrogen antagonist used adjunctively in prostatic cancer

Description:

Systemic concentrations of Te, E2, GH, IGF-I and insulin growth factor binding protein 3 (IGFBP-3) decline in healthy aging men and women. Relative sex-steroid deprivation accentuates GH and IGF-I depletion, since Te stimulates GH and IGF-I production in older men, hypogonadal males of all ages, and patients undergoing (genotypic female-to-male) gender reassignment. The estrogen-receptor antagonist, tamoxifen, blocks this effect of Te, suggesting involvement of E2 in GH's stimulation at least in young men. E2 alone stimulates GH secretion in young and older women. Because Te is converted to E2 by aromatization in the body, we postulate that E2 is the active moiety in both men and women. Moreover, we hypothesize that the decline of E2 in older men and women contributes to the fall in GH output. These basic concepts will be tested here.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: May 2016
• Est. primary completion date: May 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 50 Years to 80 Years

Eligibility

Inclusion:

1. 40 healthy women and men (ages 50 to 80 y); women will be post-menopausal (clinically defined by E2 < 50 pg/mL, FSH > 30Iu/L)

2. BMI 18-35 kg/m2

3. community dwelling; and voluntarily consenting

Exclusion:

1. recent use of psychotropic or neuroactive drugs (within five biological half-live);

2. obesity (outside weight range above);

3. Laboratory test results not deemed physician acceptable, viz potassium <3.5 mEq/L, magnesium <1.5 mEq/L, triglycerides > 300, BUN >30 or creatinine > 1.5 mg/dL, liver functions tests twice upper limit of normal, anemia (hemoglobin must meet Blood Bank requirements - Hgb = 12.5 g/dL)

4. drug or alcohol abuse, psychosis, depression, mania or severe anxiety;

5. acute or chronic organ-system disease, including renal failure (creatinine > 1.5 mg/dL)

6. endocrinopathy, other than primary thyroidal failure receiving replacement

7. nightshift work or recent transmeridian travel (exceeding 3 time zones within 7 days of admission),

8. acute weight change (loss or gain of > 2 kg in 6 weeks);

9. allergy to toremifene

10. unwillingness to provide written informed consent.

11. PSA > 4.0 ng/mL in men

12. History or suspicion of prostatic disease (elevated PSA, indeterminate nodule or mass, obstructive uropathy, or breast cancer),

13. Other carcinoma (excluding localized basal cell carcinoma removed or surgically treated with no recurrence).

14. History of thrombotic arterial disease (stroke, TIA, MI, angina) or deep vein thrombophlebitis.

15. History of CHF, cardiac arrhythmias, congenital QT prolongation, and medications used to treat cardiac arrhythmias or other strong CYP3A4 inhibitors.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Normal Healthy Volunteers

Intervention

Drug:
• Toremifene

• Placebo

• GHRH/Ghrelin combined Injection

Locations

Country	Name	City	State
United States	Mayo Clinic in Rochester	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Summed mass of growth hormone over 10 hours	Subjects will be given toremifene/placebo on Day 1 to take for 10 days. For one night between Days 8-12, from date of randomization, subjects will undergo a 12-h overnight (2200-1000h) fasting, every 10-min blood sampling. The primary analytical outcome is the summed mass of growth hormone (ie. mean/min/max) secreted in pulses over the first 10h of overnight blood samples. Pulsatile growth hormone is relevant, since sex-steroid hormones and regulatory peptides uniquely control growth hormone secretory-burst mass	Participants will be followed for an average of 2 months with growth hormone measurements occuring 10 days after initiating study medication administration.	Yes
Secondary	Growth hormone responsiveness over last 2h	Subjects will be given toremifene/placebo on Day 1 to take for 10 days. For one night between Days 8-12, from date of randomization, subjects will undergo a 12-h overnight (2200-1000h) fasting, every 10-min blood sampling. The secondary analytical outcome is growth hormone responsiveness over the last 2 hours to bolus GHRH/ghrelin stimulation (ie. mean/min/max).	Participants will be followed for an average of 2 months with growth hormone measurements occuring 10 days after initiating study medication administration	Yes